These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, DeLeo AB. Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724 [Abstract] [Full Text] [Related]
3. Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells. Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T. Clin Cancer Res; 2005 Feb 01; 11(3):1312-8. PubMed ID: 15709203 [Abstract] [Full Text] [Related]
4. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes. Tahara K, Takesako K, Sette A, Celis E, Kitano S, Akiyoshi T. Clin Cancer Res; 1999 Aug 01; 5(8):2236-41. PubMed ID: 10473111 [Abstract] [Full Text] [Related]
5. Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Gnjatic S, Bressac-de Paillerets B, Guillet JG, Choppin J. Eur J Immunol; 1995 Jun 01; 25(6):1638-42. PubMed ID: 7542198 [Abstract] [Full Text] [Related]
6. A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs. Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Itoh K. J Immunol; 1999 Nov 01; 163(9):4994-5004. PubMed ID: 10528204 [Abstract] [Full Text] [Related]
7. A parathyroid-hormone-related-protein (PTH-rP)-specific cytotoxic T cell response induced by in vitro stimulation of tumour-infiltrating lymphocytes derived from prostate cancer metastases, with epitope peptide-loaded autologous dendritic cells and low-dose IL-2. Correale P, Micheli L, Vecchio MT, Sabatino M, Petrioli R, Pozzessere D, Marsili S, Giorgi G, Lozzi L, Neri P, Francini G. Br J Cancer; 2001 Nov 30; 85(11):1722-30. PubMed ID: 11742494 [Abstract] [Full Text] [Related]
17. Identification of an HLA-A*0201 restricted Bcl2-derived epitope expressed on tumors. Wang M, Johansen B, Nissen MH, Thorn M, Kløverpris H, Fomsgaard A, Buus S, Claësson MH. Cancer Lett; 2007 Jun 18; 251(1):86-95. PubMed ID: 17182178 [Abstract] [Full Text] [Related]
18. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme. Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ. Clin Cancer Res; 2005 May 01; 11(9):3446-54. PubMed ID: 15867247 [Abstract] [Full Text] [Related]
19. Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J. J Immunol; 1998 Jan 01; 160(1):328-33. PubMed ID: 9551988 [Abstract] [Full Text] [Related]